New approaches to antiglaucoma therapy

Journal of Medicinal Chemistry

Volumn 40, Issue 18, 1997, Pages 2793-2809

  Sugrue, Michael F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 ANILINOADENOSINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 9 (3 METHYL 2 BUTENYLOXY) 1H 3 BENZAZEPINE; ACECLIDINE; ACETAZOLAMIDE; ADENOSINE RECEPTOR STIMULATING AGENT; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DOPAMINE RECEPTOR STIMULATING AGENT; DORZOLAMIDE; ENDOTHELIN; EYE DROPS; GUANYLATE CYCLASE ACTIVATOR; LATANOPROST; LEVOBUNOLOL; MEDETOMIDINE; METHAZOLAMIDE; METIPRANOLOL; MOXONIDINE; OXYMETAZOLINE; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RIMONABANT; TIMOLOL; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; BLOOD EYE BARRIER; CHOROID; CILIARY BODY; GLAUCOMA; HUMAN; INTRACAMERAL DRUG ADMINISTRATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; IRIS; LOW TENSION GLAUCOMA; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR; SIDE EFFECT; TOPICAL DRUG ADMINISTRATION; TRABECULAR MESHWORK;

ADENOSINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CANNABINOIDS; DRUG DESIGN; ENDOTHELINS; GLAUCOMA; GUANYLATE CYCLASE; HUMANS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS;

EID: 0030771463     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9608725     Document Type: Review

References (243)

1. Sugrue, M. F. The pharmacology of antiglaucoma drugs. Pharmacol. Ther. 1989, 43, 91-138.
2. Sommer, A.; Tielsch, J. M.; Katz, J.; Quigley, H. A.; Gottsch, J. D.; Javitt, J. C.; Martone, J. P.; Royall, R. M.; Witt, K. A.; Ezrine, S. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N. Engl. J. Med. 1991, 325, 1412-1417.
3. Quigley, H. A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80, 389-393.
4. Liesegang, T. J. Glaucoma: changing concepts and future directions. Mayo Clin. Proc. 1996, 71, 689-694.
5. Tielsch, J. M. The epidemiology and control of open angle glaucoma: a population-based perspective. Annu. Rev. Public Health 1996, 17, 121-136.
6. Quigley, H. A. Open-angle glaucoma. N. Engl. J. Med. 1993, 328, 1097-1106.
7. 2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography. Ophthalmic Res. 1989, 21, 309-314.
8. Matsuo, T.; Cynader, M. S. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992, 24, 213-219.
9. 2 adrenoceptors. Curr. Eye Res. 1992, 11, 963-970.
10. Hieble, J. P.; Bondinell, W. E.; Ruffolo, R. R., Jr. α- and β-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. 1995, 38, 3415-3444.
11. 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest. Ophthalmol. Vis. Sci. 1995, 36, 2729-2739.
12. Novack, G. D.; Robin, A. L.; Derick, R. J. New medical treatments for glaucoma. Int. Ophthalmol. Clin. 1993, 33, 183-202.
13. Robin, A. L. Questions concerning the role of apraclonidine in the management of glaucoma. Arch. Ophthalmol. 1995, 113, 712-714.
14. Coleman, A. L.; Robin, A. L.; Pollack, I. P.; Rudikoff, M. T.; Enger, C.; Mayer, P. R. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch. Ophthalmol. 1990, 108, 1264-1267.
15. Morrison, J. C.; Robin, A. L. Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology 1989, 96, 3-7.
16. Stewart, W. C.; Ritch, R.; Shin, D. H.; Lehmann, R. P.; Shrader, C. E.; van Buskirk, E. M.; and the Apraclonidine Adjunctive Therapy Study Group. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch. Ophthalmol. 1995, 113, 287-292.
17. Araujo, S. V.; Bond, J. B.; Wilson, R. P.; Moster, M. R.; Schmidt, C. M., Jr.; Spaeth, G. L. Long term effect of apraclonidine. Br. J. Ophthalmol. 1995, 79, 1098-1101.
18. Butler, P.; Mannschreck, M.; Lin, S.; Hwang, I.; Alvarado, J. Clinical experience with the long-term use of 1% apraclonidine, incidence of allergic reactions. Arch. Ophthalmol. 1995, 113, 293-296.
19. Gharagozloo, N. Z.; Relf, S. J.; Brubaker, R. F. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988, 95, 1217-1220.
20. Toris, C. B.; Tafoya, M. E.; Camras, C. B.; Yablonski, M. E. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995, 102, 456-461.
21. 2-agonist for the characterization of α-adrenoceptor subtypes. Eur. J. Pharmacol. 1981, 72, 413-415.
22. Nordlund, J. R.; Pasquale, L. R.; Robin, A. L.; Rudikoff, M. T.; Ordman, J.; Chen, K. S.; Walt, J. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch. Ophthalmol. 1995, 113, 77-83.
23. Toris, C. B.; Gleason, M. L.; Camras, C. B.; Yablonski, M. E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 1995, 113, 1514-1517.
24. Potter, D. E.; Ogidigben, M. J. Medetomidine-induced alterations of intraocular pressure and contraction of the nictitating membrane. Invest. Ophthalmol. Vis. Sci. 1991, 32, 2799-2805.
25. MacDonald, E.; Scheinin, M.; Scheinin, H.; Virtanen, R. Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2-adrenoceptor agonist. J. Pharmacol. Exp. Ther. 1991, 259, 848-854.
26. Vartiainen, J.; MacDonald, E.; Urtti, A.; Rouhiainen, H.; Virtanen, R. Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. Invest. Ophthalmol. Vis. Sci. 1992, 33, 2019-2023.
27. Wang, R.-F.; Lee, P.-Y.; Taniguchi, T.; Becker, B.; Podos, S. M.; Serle, J. B.; Mittag, T. W. Effect of oxymetazoline on aqueous humor dynamics and ocular blood flow in monkeys and rabbits. Arch. Ophthalmol. 1993, 111, 535-538.
28. Michel, M. C.; Ernsberger, P. Keep an eye on the I-site: Imidazoline-preferring receptors. Trends Pharmacol. Sci. 1992, 13, 369-370.
29. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 1993, 264, 172-182.
30. Ogidigben, M.; Chu, T.-C.; Potter, D. E. Ocular actions of moxonidine: a possible role for imidazoline receptors. J. Pharmacol. Exp. Ther. 1994, 269, 897-904.
31. Campbell, W. R.; Potter, D. E. Centrally mediated ocular hypotension: potential role of imidazoline receptors. Ann. N.Y. Acad. Sci. 1995, 763, 463-485.
32. Zimmerman, T. J. Topical ophthalmic beta blockers: a comparative review. J. Ocular Pharmacol. 1993, 9, 373-384.
33. Sorensen, S. J.; Abel, S. R. Comparison of the ocular beta-blockers. Ann. Pharmacother. 1996, 30, 43-54.
34. Frishman, W. H.; Fuksbrumer, M. S.; Tannenbaum, M. Topical ophthalmic β-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J. Clin. Pharmacol. 1994, 34, 795-803.
35. Brooks, A. M. V.; Gillies, W. E. Ocular β-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992, 2, 208-221.
36. Diggory, P.; Franks, W. Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol. 1996, 80, 85-89.
37. Zimmerman, T. J.; Sharir, M.; Nardin, G. F.; Fuqua, M. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am. J. Ophthalmol. 1992, 114, 1-7.
38. Laurence, J.; Holder, D.; Vogel, R.; Gross, R. L.; Haik, B. G.; Karp, D. W.; Koby, M. M.; Zimmerman, T. J. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J. Glaucoma 1993, 2, 177-182.
39. Rozier, A.; Mazuel, C.; Grove, J.; Plazonnet, B. Gelrite®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm. 1989, 57, 163-168.
40. Dickstein, K.; Aarsland, T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am. J. Ophthalmol. 1996, 121, 367-371.
41. Bodor, N. Retrometabolic drug design concepts in ophthalmic target-specific drug delivery. Adv. Drug Del. Rev. 1995, 16, 21-38.
42. El-Koussi, A.; Bodor, N. Formation of propranolol in the iris-ciliary body from its propranolol ketoxime precursor - a potential antiglaucoma drug. Int. J. Pharm. 1989, 53, 189-194.
43. Bodor, N.; Elkoussi, A. Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime - A new potential antiglaucoma agent. Pharm. Res. 1991, 8, 1389-1395.
44. Polgar, P.; Bodor, N. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular β-blocker, in dogs. Life Sci. 1995, 56, 1207-1213.
45. Bodor, N.; Prokai, L.; Wu, W.; Somogyi, G.; Farag, H. Sequential bioactivation of methoxime analogs of β-adrenergic antagonists in the eye. J. Ocular Pharmacol. Ther. 1995, 11, 305-318.
46. Prokai, L.; Wu, W.; Somogyi, G.; Bodor, N. Ocular delivery of the β-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue. J. Med. Chem. 1995, 38, 2018-2020.
47. Bodor, N. Designing safer ophthalmic drugs by soft drug approaches. J. Ocular Pharmacol. 1994, 10, 3-15.
48. Sugrue, M. F.; Gautheron, P.; Grove, J.; Mallorga, P.; Viader, M.; Baldwin, J. J.; Ponticello, G. S.; Varga, S. L. L-653,328: an ocular hypotensive agent with modest beta receptor blocking activity. Invest. Ophthalmol. Vis. Sci. 1988, 29, 776-784.
49. Bauer, K.; Brunner-Ferber, F.; Distlerath, L. M.; Lippa, E. A.; Binkowitz, B.; Till, P.; Kaik, G. Assessment of systemic effects of different ophthalmic β-blockers in healthy volunteers. Clin. Pharmacol. Ther. 1991, 49, 658-664.
50. Bauer, K. G.; Brunner-Ferber, F.; Distlerath, L. M.; Lippa, E. A.; Binkowitz, B.; Till, P.; Kaik, G. A. Assessment of bronchial effects following topical administration of butylamino-phenoxypropanol-acetate, an oculoselective β-adrenoceptor blocker in asthmatic subjects. Br. J. Clin. Pharmacol. 1992, 34, 122-129.
51. Boder, N.; Elkoussi, A.; Zuobi, K.; Kovacs, P. Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. J. Ocular Pharmacol. Ther. 1996, 12, 115-122.
52. 2 binding sites. Curr. Eye Res. 1989, 8, 75-83.
53. Karnezis, T. A.; Tripathi, B. J.; Dawson, G.; Murphy, M. B.; Tripathi, R. C. Effects of dopamine receptor activation on the level of cyclic AMP in the trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 1989, 30, 1090-1094.
54. 1 receptors in the bovine ciliary body. Exp. Eye Res. 1990, 51, 495-501.
55. 1-like receptor sites in the ciliary body of the rabbit eye by light microscope autoradiography. Naunyn-Schmiedeberg's Arch. Pharmacol. 1992, 346, 664-648.
56. Wax, M. B. Does dopamine act at dopamine receptors in the ciliary epithelia? Exp. Eye Res. 1993, 56, 371-373.
57. 2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine. J. Pharmacol. Exp. Ther. 1993, 267, 822-827.
58. Potter, D. E.; Ogidigben, M. J.; Heath, A. R. Ocular actions of an octahydrobenzo[f]quinoline: Ha117. Eur. J. Pharmacol. 1993, 236, 61-68.
59. Ogidigben, M. J.; Potter, D. E. Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits. J. Ocular Pharmacol. 1993, 9, 187-199.
60. Hariton, C. Biphasic dose-dependent effects of dopamine and involvement of dopamine autoreceptors on intra-ocular pressure in the rabbit. J. Auton. Pharmacol. 1992, 12, 335-347.
61. Hariton, C. Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur. J. Pharmacol. 1994, 258, 85-94.
62. Prünte, C.; Flammer, J. The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma. Ophthalmology 1995, 102, 1291-1297.
63. Caulfield, M. P. Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. 1993, 58, 319-379.
64. Ringdahl, B. Structural determinants of muscarinic agonist activity. In The Muscarinic Receptors; Brown, J. H., Ed.; Humana Press: Clifton, NJ, 1989; pp 151-218.
65. Davis, R.; Raby, C.; Callahan, M. J.; Lipinski, W.; Schwarz, R.; Dudley, D. T.; Lauffer, D.; Reece, P.; Jaen, J.; Tecle, H. Subtype selective muscarinic agonists - potential therapeutic agents for Alzheimer's disease. Progr. Brain Res. 1993, 98, 439-445.
66. Erickson-Lamy, K.; Schroeder, A. Dissociation between the effect of aceclidine on outflow facility and accommodation. Exp. Eye Res. 1990, 50, 143-147.
67. Lepple-Wienhues, A.; Stahl, F.; Wiederholt, M. Differential smooth muscle-like contractile properties of trabecular meshwork and ciliary muscle. Exp. Eye Res. 1991, 53, 33-38.
68. Honkanen, R. E.; Howard, E. F.; Abdel-Latif, A. A. M3-muscarinic receptor subtype predominates in the bovine iris sphincter smooth muscle and ciliary processes. Invest. Ophthalmol. Vis. Sci. 1990, 31, 590-593.
69. 3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res. 1994, 26, 207-213.
70. Shade, D. L.; Clark, A. F.; Pang, I. Effects of muscarinic agents on cultured human trabecular meshwork cells. Exp. Eye Res. 1996, 62, 201-210.
71. Gabelt, A. T.; Kaufman, P. L. Inhibition of aceclidine-stimulated outflow facility, accommodation and miosis in rhesus monkeys by muscarinic receptor subtype antagonists. Exp. Eye Res. 1994, 58, 623-630.
72. Järvinen, T.; Suhonen, P.; Auriola, S.; Vepsäläinen, J.; Urtti, A.; Peura, P. O,O′-(1,4-Xylylene) bispilocarpic acid esters as new potential double prodrugs of pilocarpine for improved ocular delivery. I. Synthesis and analysis. Int. J. Pharm. 1991, 75, 249-258.
73. Sugrue, M. F. Review: the preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J. Ocular Pharmacol. Ther. 1996, 12, 363-376.
74. Sly, W. S.; Hu, P. Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu. Rev. Biochem. 1995, 64, 375-401.
75. Maren, T. H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma 1995, 4, 49-62.
76. Hageman, G. S.; Zhu, X. L.; Waheed, A.; Sly, W. S. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2716-2720.
77. Krupin, T.; Sly, W. S.; Whyte, M. P.; Dodgson, S. J. Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am. J. Ophthalmol. 1985, 99, 396-399.
78. Maren, T. H. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol. Rev. 1967, 47, 595-781.
79. Smith, G. M.; Alexander, R. S.; Christianson, D. W.; McKeever, B. M.; Ponticello, G. S.; Springer, J. P.; Randall, W. C.; Baldwin, J. J.; Habecker, C. N. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 1994, 3, 118-125.
80. Sugrue, M. F.; Mallorga, P.; Schwam, H.; Baldwin, J. J.; Ponticello, G. S. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr. Eye Res. 1990, 9, 607-615.
81. Serle, J. B.; Podos, S. M. Topical carbonic anhydrase inhibitors in the treatment of glaucoma. Ophthalmol. Clin. North Am. 1995, 8, 315-325.
82. Strahlman, E.; Tipping, R.; Vogel, R. and the International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol. 1995, 113, 1009-1016.
83. Biollaz, J.; Munafo, A.; Buclin, T.; Gervasoni, J.-P.; Magnin, J.-L.; Jaquet, F.; Brunner-Ferber, F. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Clin. Pharmacol. 1995, 47, 453-460.
84. Strahlman, E. R.; Vogel, R.; Tipping, R.; Clineschmidt, C. M.; the Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996, 103, 1283-1293.
85. Laibovitz, R.; Strahlman, E. R.; Barber, B. L.; Strohmaier, K. M. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J. Glaucoma 1995, 4, 306-313.
86. Harris, A.; Arend, O.; Arend, S.; Martin, B. Effect of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol. 1996, 74, 569-572.
87. Wang, R.-F.; Serle, J. B.; Podos, S. M.; Sugrue, M. F. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch. Ophthalmol. 1991, 109, 1297-1299.
88. Maus, T. L.; Larsson, L.-I.; McLaren, J. W.; Brubaker, R. F. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. 1997, 115, 45-49.
89. Dean, T.; Chen, H. H.; May, J.; McLaughlin, M.; DeSantis, L. AL-4414A and AL-4623A are new topically active carbonic anhydrase inhibitors which demonstrate a long lasting ocular hypotensive effect in the lasered cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 1993, 34, 931.
90. Chiang, C.-H.; Lee, A.-R.; Lin, C.-H. Studies of topical carbonic anhydrase inhibitors: ocular hypotensive effect of thiadiazole derivatives. J. Ocular Pharmacol. 1993, 9, 109-115.
91. Sharir, M.; Pierce, W. M., Jr.; Chen, D.; Zimmerman, T. J. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide - a novel topically active carbonic anhydrase inhibitor. Exp. Eye Res. 1994, 58, 107-116.
92. Brechue, W. F.; Maren, T. H. Carbonic anhydrase inhibitory activity and ocular pharmacology of organic sulfamates. J. Pharmacol. Exp. Ther. 1993, 264, 670-675.
93. Loftsson, T.; Frióriksdóttir, H.; Thórisdóttir, S.; Stefánsson, E.; Siguróardóttir, A. M.; Guómundsson, Ö.; Sigthórsson, T. 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur. J. Pharm. Sci. 1994, 1, 175-180.
94. Coleman, R. A.; Humphrey, P. P. A.; Kennedy, I.; Lumley, P. Prostanoid receptors - the development of a working classification. Trends Pharmacol. Sci. 1984, 5, 303-306.
95. Coleman, R. A.; Smith, W. L.; Narumiya, S. Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46, 205-229.
96. 2 binding sites in bovine iris-ciliary body. Invest. Ophthalmol. Vis. Sci. 1990, 31, 1109-1113.
97. 2α binding sites in the bovine iris ciliary body. Invest. Ophthalmol. Vis. Sci., 34, 2237-2245.
98. 2 binding site distribution and subtype classification in the rabbit iris-ciliary body. Prostaglandins 1992, 44, 199-208.
99. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis. Sci. 1996, 37, 716-726.
100. 2 binding sites in the human eye. Br. J. Ophthalmol. 1992, 76, 210-213.
101. 2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br. J. Ophthalmol. 1993, 77, 110-114.
102. Ohia, S. E.; Jumblatt, J. E. Prejunctional prostaglandin receptors in the human iris-ciliary body. Curr. Eye Res. 1991, 10, 967-975.
103. Yousufzai, S. Y. K.; Chen, A.-L.; Abdel-Latif, A. A. Species differences in the effects of prostaglandins on inositol trisphosphate accumulation, phosphatidic acid formation, myosin light chain phosphorylation and contraction in iris sphincter of the mammalian eye: interaction with the cyclic AMP system. J. Pharmacol. Expl. Ther. 1988, 247, 1064-1072.
104. Bhattacherjee, P.; Paterson, C. A. Studies on prostanoid receptors in ocular tissues. J. Ocular Pharmacol. 1994, 10, 167-175.
105. Bhattacherjee, P.; Rhodes, L.; Paterson, C. A. Prostaglandin receptors coupled to adenylyl cyclase in the iris-ciliary body of rabbits, cats and cows. Exp. Eye Res. 1993, 56, 327-333.
106. 2α effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest. Ophthalmol. Vis. Sci. 1989, 30, 1838-1842.
107. 2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest. Ophthalmol. Vis. Sci. 1990, 31, 2560-2567.
108. 2 effects on normal human intraocular pressure. J. Ocular Pharmacol. 1988, 4, 13-18.
109. Protzman, C. E.; Woodward, D. F. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype. Invest. Ophthalmol. Vis. Sci. 1990, 31, 2463-2466.
110. 2. Invest. Ophthalmol. Vis. Sci. 1990, 31, 138-146.
111. 2 and its analogue, BW245C, on intraocular pressure in humans. Graefe's Arch. Clin. Exp. Ophthalmol. 1991, 229, 411-413.
112. Woodward, D. P.; Lawrence, R. A.; Fairbairn, C. E.; Shan, T.; Williams, L. S. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J. Lipid Mediators 1993 6, 545-553.
113. 2 receptor. J. Ocular Pharmacol. Ther. 1995, 11, 447-454.
114. 2 receptors and the corresponding mRNAs in human eye tissue. Br. J. Ophthalmol 1994, 78, 921-926.
115. 2-mimetic with ocular hypotensive properties. J. Ocular Pharmacol. Ther. 1995, 11, 203-212.
116. 2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989, 96, 1329-1337.
117. 2α esters. A doublemasked cross-over study on normotensive eyes. Acta Ophthalmol. 1990, 68, 341-343.
118. 2α analog, PhXA41 (latanoprost), for glaucoma management. J. Lipid Mediators 1993, 6, 535-543.
119. 2α. Br. J. Ophthalmol. 1994, 78, 560-567.
120. Resul, B.; Stjernschantz, J.; No, K.; Liljebris, C.; Selén. G.; Astin, M.; Karlsson, M.; Bito, L. Z. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. J. Med. Chem. 1993, 36, 243-248.
121. Basu, S.; Sjöquist, B.; Stjernschantz, J.; Resul, B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins, Leukotrienes Essent. Fatty Acids 1994, 50, 161-168.
122. Stjernschantz, J.; Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992, 17, 671-704.
123. 2α analogue. Effect on intraocular pressure in patieents with ocular hypertension. Br. J. Ophthalmol. 1992, 76, 214-217.
124. Alm, A.; Villumsen, J.; Tornquist, P.; Mandahl, A.; Airaksinen, J.; Tuulonen, A.; Marsk, A.; Resul, B.; Stjernschantz, J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993, 100, 1312-1317.
125. 2α analogue (PhXA41). An in-hospital, placebo-controlled study. Arch. Ophthalmol. 1993, III, 657-661.
126. 2α analogue, and timolol in patients with elevated intraocular pressure. Br. J. Ophthalmol. 1994, 78, 899-902.
127. Camras, C. B.; the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996, 103, 138-147.
128. Watson, P.; Stjernschantz, J.; the Latanoprost Study Group. A Six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996, 103, 126-137.
129. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993, 100, 1297-1304.
130. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 1993, III, 1351-1358.
131. Camras, C. B. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research; Samuelson, B., et al., Eds.; Raven Press, Ltd.: New York, 1995; pp 519-525.
132. Bill, A. Some aspects of aqueous humour drainage. Eye 1993, 7, 14-19.
133. Azuma, I.; Masuda, K.; Kitazawa, Y.; Takase, M.; Yamamura, H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn. J. Ophthalmol. 1993, 37, 514-525.
134. Sakurai, M.; Araie, M.; Oshika, T.; Mori, M.; Masuda, K.; Ueno, R.; Takase, M. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn. J. Ophthalmol. 1991, 35, 156-165.
135. Ando, Y.; Matsunami, C.; Yamamoto, T.; Kitazawa, Y. Ocular hypotensive effect of a new prostaglandin analogue, S-1033, in normal human volunteers. Jpn. J. Ophthalmol. 1994, 38, 337-342.
136. Goh, Y.; Oshima, T.; Araie, M. Mechanism of intraocular pressure reduction observed after topical application of S-1033 in animals. Jpn. J. Ophthalmol. 1994, 38, 228-235.
137. Goh, Y.; Kishino, J. Pharmacological characterization of prostaglandin-related ocular hypotensive agents. Jpn. J. Ophthalmol. 1994, 38, 236-245.
138. Erickson-Lamy, K.; Schroeder, A.; Epstein, D. L. Ethacrynic acid induces reversible shape and cytoskeletal changes in cultured cells. Invest. Ophthalmol. Vis. Sci. 1992, 33, 2631-2640.
139. Liang, L-L.; Epstein, D. L.; de Kater, A. W.; Shahsafaei, A.; Erickson-Lamy, K. A. Ethacrynic acid increases facility of outflow in the human eye in vitro. Arch. Ophthalmol. 1992, 110, 106-109.
140. Johnson, D. H.; Tschumper, R. C. Ethacrynic acid: outflow effects and toxicity in human trabecular meshwork in perfusion organ culture. Curr. Eye Res. 1993, 12, 385-396.
141. Melamed, S.; Kotas-Neumann, R.; Barak, A.; Epstein, D. L. The effect of intracamerally injected ethacrynic acid on intraocular pressure in patients with glaucoma. Am. J. Ophthalmol. 1992, 113, 508-512.
142. Tingey, D. P.; Ozment, R. R.; Schroeder, A.; Epstein, D. L. The effect of intracameral ethacrynic acid on the intraocular pressure of living monkeys. Am. J. Ophthalmol. 1992, 113, 706-711.
143. Epstein, D. L.; Hooshmand, L. B.; Epstein, M. P. M. Thiol adducts of ethacrynic acid increase outflow facility in enucleated calf eyes. Curr. Eye Res. 1992, 11, 253-258.
144. Tingey, D. P.; Schroeder, A.; Epstein, M. P. M.; Epstein, D. L. Effects of topical ethacrynic acid adducts on intraocular pressure in rabbits and monkeys. Arch. Ophthalmol. 1992, 110, 699-702.
145. Wang, R.-F.; Podos, S. M.; Serle, J. B.; Lee, P.-Y.; Neufeld, A. H.; Deschenes, R. Effects of topical ethacrynic acid ointment vs timolol on intraocular pressure in glaucomatous monkey eyes. Arch. Ophthalmol. 1994, 112, 390-394.
146. Croft, M. A.; Kaufman, P. L. Effect of daily topical ethacrynic acid on aqueous humor dynamics in monkeys. Curr. Eye Res. 1995, 14, 777-781.
147. Croft, M. A.; Hubbard, W. C.; Kaufman, P. L. Effect of ethacrynic acid on aqueous outflow dynamics in monkeys. Invest. Ophthalmol. Vis. Sci. 1994, 35, 1167-1175.
148. Palfrey, H. C.; Leung, S. Inhibition of Na-K-2Cl cotransport and bumetanide binding by ethacrynic acid, its analogues, and adducts. Am. J. Physiol. 1993, 264 (Cell Physiol. 33), C1270-C1277.
149. O'Donnell, M. E.; Brandt, J. D.; Curry, F-R. E. Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am. J. Physiol. 1995, 268 (Cell Physiol. 37), C1067-C1074.
150. Payne, J. A.; Forbush, B., III. Molecular characterization of the epithelial Na-K-Cl cotransporter isoforms. Curr. Opin. Cell Biol. 1995, 7, 493-503.
151. Becker, B. Topical 8-bromo-cyclic GMP lowers intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci. 1990, 31, 1647-1649.
152. Kee, C.; Kaufman, P. L.; Gabelt, B. T. Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. Invest. Ophthalmol. Vis. Sci. 1994, 35, 2769-2773.
153. Korenfeld, M. S.; Becker, B. Atrial Natriuretic Peptides. Effects on intraocular pressure, cGMP and aqueous flow. Invest. Ophthalmol. Vis. Sci. 1989, 30, 2385-2392.
154. Samuelsson-Almén, M.; Nilsson, S. F. E.; Mäepea, O.; Bill, A. Effects of atrial natriuretic factor (ANF) on intraocular pressure and aqueous humor flow in the cynomolgus monkey. Exp. Eye Res. 1991, 53, 253-260.
155. Diestelhorst, M.; Krieglstein, G. K. The intraocular pressure response of human atrial natriuretic factor in glaucoma. Int. Ophthalmol. 1989, 13, 99-101.
156. Connell, J. M. C.; Jardine, A. G.; Northridge, D. B. Therapeutic use of atrial natriuretic factor. Br. J. Clin. Pharmacol. 1992, 34, 102-105.
157. Wolfensberger, T. J.; Singer, D. R. J.; Freegard, T.; Markandu, N. D.; Buckley, M. G.; MacGregor, G. A. Evidence for a new role of natriuretic peptides: control of intraocular pressure. Br. J. Ophthalmol. 1994, 78, 446-448.
158. Nathanson, J. A. Nitrovasodilators as a new class of ocular hypotensive agents. J. Pharmacol. Exp. Ther. 1992, 260, 956-965.
159. Schuman, J. S.; Erickson, K.; Nathanson, J. A. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp. Eye Res. 1994, 58, 99-105.
160. Wang, R.-F.; Podos, S. M. Effect of the topical application of nitroglycerin on intraocular pressure in normal and glaucomatous monkeys. Exp. Eye Res. 1995, 60, 337-339.
161. Nathanson, J. A. Nitric oxide and nitrovasodilators in the eye: Implications for ocular physiology and glaucoma. J. Glaucoma 1993, 2, 206-210.
162. Pang, I.-H.; Shade. D. L.; Matsumoto, S.; Steely, H. T.; DeSantis, L. Presence of functional type B natriuretic peptide receptor in human ocular cells. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1724-1731.
163. Larsson, L.-I.; Maus, T. L.; Brubaker, R. F.; Nathanson, J. A. Topically applied hydralazine: effects on systemic cardiovascular parameters, blood-aqueous barrier, and aqueous humor dynamics in normotensive humans. J. Ocular Pharmacol. Ther. 1995, 11, 145-156.
164. Bredt, D. S.; Snyder, S. H. Nitric oxide, a novel neuronal messenger. Neuron 1992, 8, 3-11.
165. Kerwin, J. F., Jr.; Lancaster, J. R., Jr.; Feldman, P. L. Nitric oxide: a new paradigm for second messengers. J. Med. Chem. 1995, 38, 4343-4362.
166. Yamamoto, R.; Bredt, D. S.; Snyder, S. H.; Stone, R. A. The localization of nitric oxide synthase in the rat eye and related cranial ganglia. Neuroscience 1993, 54, 189-200.
167. Osborne, N. N.; Barnett, N. L.; Herrera, A. J. NADPH diaphorase localization and nitric oxide synthetase activity in the retina and anterior uvea of the rabbit eye. Brain Res. 1993, 610, 194-198.
168. Nathanson, J. A.; McKee, M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest. Ophthalmol. Vis. Sci. 1995, 36, 1765-1773.
169. Nathanson, J. A.; McKee, M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest. Ophthalmol. Vis. Sci. 1995, 36, 1774-1784.
170. Behar-Cohen, F. F.; Goureau, O.; D'Hermies, F.; Courtois, Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1711-1715.
171. Melvin, L. S.; Milne, G. M.; Johnson, R. M.; Subramaniam, B.; Wilken, G. H.; Hewlett, A. C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 1993, 44, 1008-1015.
172. D'Ambra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem. 1992, 35, 124-135.
173. Sugrue, M. F.; Funk, H. A.; Leonard, Y.; O'Neill-Davis, L.; Labelle, M. The ocular hypotensive effects of synthetic cannabinoids. Invest. Ophthalmol. Vis. Sci. 1996, 37, S831.
174. Hewlett, A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 607-634.
175. Devane, W. A.; Dysarz, F. A., III; Johnson, M. R.; Melvin, L. S.;
176. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
177. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
178. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
179. Pate, D. W.; Järvinen, K.; Urtti, A.; Jarho, P.; Järvinen, T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr. Eye Res. 1995, 14, 791-797.
180. Pate, D. W.; Järvinen, K.; Urtti, A.; Jarho, P.; Fich, M.; Mahadevan, V.; Järvinen, T. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci. 1996, 58, 1849-1860.
181. Kuster, J. E.; Stevenson, J. I.; Ward, S. J.; D'Ambra, T. E.; Haycock, D. A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 1993, 264, 1351-1363.
182. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Néliat, G.; Caput, D.; Ferrara, P.; Soubrié, P.; Brelière, J. C.; Le Fur, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244.
183. 2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
184. 3H]-SR141716A. NeuroReport 1996, 7, 789-792.
185. Song, Z.-H.; Bonner, T. I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol. 1996, 49, 891-896.
186. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332, 411-415.
187. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
188. MacCumber, M. W.; Ross, C. A.; Glaser, B. M.; Snyder, S. H. Endothelin: visualization of mRNAs by in situ hybridization provides evidence for local action. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7285-7289.
189. Eichhorn, M.; Lütjen-Drecoll, E. Distribution of endothelin-like immunoreactivity in the human ciliary epithelium. Curr. Eye Res. 1993, 12, 753-757.
190. Chakravarthy, U.; Douglas, A. J.; Bailie, J. R.; McKibben, B.; Archer, D. B. Immunoreactive endothelin distribution in ocular tissues. Invest. Ophthalmol. Vis. Sci. 1994, 35, 2448-2454.
191. MacCumber, M. W.; Jampel, H. D.; Snyder, S. H. Ocular effects of the endothelins, abundant peptides in the eye. Arch. Ophthalmol. 1991, 109, 705-709.
192. B, from rat lung with retention of binding activity. Biomed. Res. 1991, 12, 417-423.
193. Lepple-Wienhues, A.; Stahl, F.; Willner, U.; Schäfer, R.; Wiederholt, M. Endothelin-evoked contractions in bovine ciliary muscle and trabecular meshwork: interaction with calcium, nifedipine and nickel. Curr. Eye Res. 1991, 10, 983-989.
194. Erickson-Lamy, K.; Korbmacher, C.; Schuman, J. S.; Nathanson, J. A. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo. Invest. Ophthalmol. Vis. Sci. 1991, 32, 492-495.
195. Taniguchi, T.; Okada, K.; Haque, M. S. R.; Sugiyama, K.; Kitazawa, Y. Effects of endothelin-1 on intraocular pressure and aqueous humor dynamics in the rabbit eye. Curr. Eye Res. 1994, 13, 461-464.
196. Granstam, E.; Wang, L.; Bill, A. Effects of endothelins (ET-1, ET-2, and ET-3) in the rabbit eye; role of prostaglandins. Eur. J. Pharmacol 1991, 194, 217-223.
197. B receptor, and cyclooxygenase products in rabbits. Curr. Eye Res. 1995, 14, 479-486.
198. Williams, D. L., Jr.; Jones, K. L.; Pettibone, D. J.; Lis, E. V.; Clineschmidt, B. V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem. Biophys. Res. Commun. 1991, 175, 556-561.
199. Haque, M. S. R.; Taniguchi, T.; Sugiyama, K.; Okada, K.; Kitazawa, Y. The ocular hypotensive effect of the ETB receptor selective agonist, sarafotoxin S6c, in rabbits. Invest. Ophthalmol. Vis. Sci. 1995, 36, 804-808.
200. Taniguchi, T.; Haque, M. S. R.; Sugiyama, K.; Okada, K.; Nakai, Y.; Kitazawa, Y. Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye. J. Ocular Pharmacol. Ther. 1996, 12, 123-130.
201. A receptor-selective antagonist, on changes of intraocular pressure, blood-aqueous barrier and aqueous prostaglandin concentrations caused by endothelin-1 in rabbit. Jpn. J. Ophthalmol. 1996, 40, 26-32.
202. Crosson, C. E. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr. Eye Res. 1992, 11, 453-458,
203. Crosson, C. E.; Gray, T. Modulation of intraocular pressure by adenosine agonists. J. Ocular Pharmacol. 1994, 10, 379-383.
204. Crosson, C. E. Adenosine receptor activation modulates intraocular pressure in rabbits. J. Pharmacol. Exp. Ther. 1995, 273, 320-326.
205. Crosson, C. E.; Gray, T. Characterization of ocular hypertension induced by adenosine agonists. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1833-1839.
206. 3H]noradrenaline release on rat iris. Naunyn-Schmiedeberg's Arch. Pharmacol. 1992, 345, 417-423.
207. Wax, M.; Sanghavi, D. M.; Lee, C. H.; Kapadia, M. Purinergic receptors in ocular ciliary epithelial cells. Exp. Eye Res. 1993, 57, 89-95.
208. 1 adenosine receptor-GTP-binding protein complexes in ciliary epithelial cells. Invest. Ophthalmol. Vis. Sci. 1994, 35, 3057-3063.
209. Flammer, J. The vascular concept of glaucoma. Surv. Ophthalmol. 1994, 38, S3-S6.
210. Hayreh, S. S. Systemic arterial blood pressure and the eye. Eye 1996, 10, 5-28.
211. Flammer, J. Therapeutic aspects of normal-tension glaucoma. Curr. Opin. Ophthalmol. 1993, 4, 58-64.
212. Orgul, S.; Flammer, J.; Gasser, P. Female preponderance in normal-tension glaucoma. Ann. Ophthalmol. 1995, 27, 355-359.
213. Van Buskirk, E. M.; Cioffi, G. A. Glaucomatous optic neuropathy. Am. J. Ophthalmol. 1992, 113, 447-452.
214. Haefliger, I. O.; Meyer, P.; Flammer, J.; Lüscher, T. F. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv. Ophthalmol. 1994, 39, 123-132.
215. Kaiser, H. J.; Flammer, J.; Wenk, M.; Lüscher, T. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefe's Arch. Clin. Exp. Ophthalmol. 1995, 233, 484-488.
216. Sugiyama, T.; Moriya, S.; Oku, H.; Azuma, I. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv. Ophthalmol. 1995, 39, S49-S56.
217. Orgül, S.; Cioffi, G. A.; Wilson, D. J.; Bacon, D. R.; Van Buskirk, E. M. An endothelin-1 induced model of optic nerve ischemia in the rabbit. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1860-1869.
218. Orgül, S.; Cioffi, G. A.; Bacon, D. R.; Van Buskirk, E. M. An endothelin-1 induced model of optic nerve ischemia in rhesus monkeys. J. Glaucoma 1996, 5, 135-138.
219. Netland, P. A.; Erickson, K. A. Calcium channel blockers in glaucoma management. Ophthalmol. Clin. North Am. 1995, 8, 327-334.
220. Netland, P. A.; Grosskreutz, C. L.; Feke, G. T.; Hart, L. J. Color doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am. J. Ophthalmol. 1995, 119, 694-700.
221. Netland, P. A.; Feke, G. T.; Konno, S.; Goger, D. G.; Fujio, N. Optic nerve head circulation after topical calcium channel blocker. J. Glaucoma 1996, 5, 200-206.
222. Erickson, K. A.; Schroeder, A.; Netland, P. A. Verapamil increases outflow facility in the human eye. Exp. Eye Res. 1995, 61, 565-567.
223. Liu, S.; Araujo, S. V.; Spaeth, G. L.; Katz, L. J.; Smith, M. Lack of effect of calcium channel blockers on open-angle glaucoma. J. Glaucoma 1996, 5, 187-190.
224. Brubaker, R. F. Delayed functional loss in glaucoma. Am. J. Ophthalmol. 1996, 121, 473-483.
225. Schumer, R. A.; Podos, S. M. The nerve of glaucoma. Arch. Ophthalmol. 1994, 112, 37-44.
226. Dreyer, E. B.; Zurakowski, D.; Schumer, R. A.; Podos, S. M.; Lipton, S. A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996, 114, 299-305.
227. Vorwerk, C. K.; Lipton, S. A.; Zurakowski, D.; Hyman, B. T.; Sabel, B. A.; Dreyer, E. B. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1618-1624.
228. Yoon, Y. H.; Marmor, M. F. Dextromethorphan protects retina against ischemic injury in vivo. Arch. Ophthalmol. 1989, 107, 409-411.
229. Osborne, N. N.; Schwarz, M.; Pergande, G. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophthalmol. Vis. Sci. 1996, 37, 274-280.
230. Osborne, N. N.; Pergande, G.; Block, F.; Schwarz, M. Immunohistochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid-induced release of GABA in the rabbit retina. Brain Res. 1994, 667, 291-294.
231. Feigenbaum, J, J.; Bergmann, F.; Richmond, S. A.; Mechoulam, R.; Nadler, V.; Kloog, Y.; Sokolovsky, M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9584-9587.
232. Yoles, E.; Belkin, M.; Schwartz, M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma 1996, 13, 49-57.
233. Lam, T. T.; Takahashi, K.; Tso, M. O. M. The effects of naloxone on retinal ischemia in rats. J. Ocular Pharmacol. 1994, 10, 481-492.
234. Buys, Y. M.; Trope, G. E.; Tatton, W. G. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr. Eye Res. 1995, 14, 119-126.
235. Geyer, O.; Almog, J.; Lupu-Meiri, M.; Lazar, M.; Oron, Y. Nitric oxide synthase inhibitors protect rat retina against ischemic injury. FEBS Lett. 1995, 374, 399-402.
236. Nickells, R. W. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J. Glaucoma 1996, 5, 345-356.
237. Sanborn, G. E.; Anand, R.; Torti, R. E.; Nightingale, S. D.; Cal, S, X.; Yates, B.; Ashton, P.; Smith, T. Sustained release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch. Ophthalmol. 1992, 110, 188-195.
238. Clark, A. F.; Lane, D.; Wilson, K.; Miggans, S. T.; McCartney, M. D. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest. Ophthalmol. Vis. Sci. 1996, 35, 805-813.
239. Fischbarg, J. A rapidly emerging field: water channel proteins in the eye. Invest. Ophthalmol. Vis. Sci. 1995, 36, 758-763.
240. Stamer, W. D.; Seftor, R. E. B.; Snyder, R. W.; Regan, J. W. Cultured human trabecular meshwork cells express aquaporin-1 water channels. Curr. Eye Res. 1995, 14, 1095-1100.
241. Alward, W. L. M.; Johnson, T. A.; Nishimura, D. Y.; Sheffield, V. C.; Stone, E. D. Molecular genetics of glaucoma: current status. J. Glaucoma 1996, 5, 276-284.
242. Stone, E. M.; Fingert, J. H.; Alward, W. L. M.; Nguyen, T. D.; Polansky, J. R.; Sunden, S. L. F.; Nishimura, D.; Clark, A. F.; Nystuen, A.; Nichols, B. E.; Mackey, D. A.; Ritch, R.; Kalenak, J. W.; Craven, E. R.; Sheffield, V. C. Identification of a gene that causes primary open angle glaucoma. Science 1997, 275, 668-670.
243. Polansky, J. R.; Fauss, D. J.; Chen, P.; Chen, H.; Lütjen-Drecoll, E.; Johnson, D.; Kurtz, R. M.; Ma, Z.-D.; Bloom, E.; Nguyen, T. D. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologia 1991, 211, 126-139.